Form 8-K - Current report:
SEC Accession No. 0001104659-24-126761
Filing Date
2024-12-09
Accepted
2024-12-09 16:15:34
Documents
13
Period of Report
2024-12-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430528d1_8k.htm   iXBRL 8-K 26318
  Complete submission text file 0001104659-24-126761.txt   201930

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA anvs-20241204.xsd EX-101.SCH 3021
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20241204_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20241204_pre.xml EX-101.PRE 22363
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2430528d1_8k_htm.xml XML 3791
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 241535293
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)